Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
B-cell Acute Lymphoblastic Leukemia: early-phase trial registry
17 of 22 indexed B-cell Acute Lymphoblastic Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #756 of 28,707 conditions by registered trial count.
22 US clinical trials · 17 currently recruiting · #756 of 28,707 conditions by registered trial count
B-cell Acute Lymphoblastic Leukemia: 22 US clinical trials tracked, 17 recruiting.
B-cell Acute Lymphoblastic Leukemia is the subject of 22 registered US clinical trials on ClinicalTrials.gov, 17 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is University of Colorado, Denver, running 2 of these trials.
Enrollment posture brief
Registry condition b-cell-acute-lymphoblastic-leukemia
OPEN 17 | RECR 77% | LATE 1 | EARLY 20 | RANK #756 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Firearm Injury (77% recruiting · 13 trials)
B-cell Acute Lymphoblastic Leukemia lists 17 open slots (77% of 22 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for B-cell Acute Lymphoblastic Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
B-cell Acute Lymphoblastic Leukemia is recruiting above its size-band peers.
17 of 22 indexed trials (77.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of B-cell Acute Lymphoblastic Leukemia trials is spread across many organizations.
University of Colorado, Denver accounts for 2 of 22 trials (9.1%). 20 distinct sponsors appear on at least one study for this condition label.
-
Most B-cell Acute Lymphoblastic Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 54 among the 22 trials that report a genuine target (sentinel values excluded). 16 of those (72.7%) plan for fewer than 100 participants.
-
B-cell Acute Lymphoblastic Leukemia research is mostly interventional.
21 interventional and 1 observational studies make up this index (95.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
22 total, page 1 of 1
A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Arkansas Children's Hospital Research Institute
NCT07422337
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Etan Orgel
NCT05082519
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Imugene Limited
NCT03666000
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
NCT07223021
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Pediatric Transplantation & Cellular Therapy Consortium
NCT03509961
Co-administration of CART22-65s and huCART19 for B-ALL
Stephan Grupp MD PhD
NCT05674175
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Merck Sharp & Dohme
NCT06395103
A Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-cell Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
NCT07153796
Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies
University of Kansas Medical Center
NCT06879340
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
University of Colorado, Denver
NCT06559189
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Cellectis S.A.
NCT04150497
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
University of Colorado, Denver
NCT04544592
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
Marlise Luskin, MD
NCT03595917
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Vincerx Pharma
NCT06034275
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics
NCT06533579
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
Children's Hospital Medical Center, Cincinnati
NCT06863259
Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT
Medical College of Wisconsin
NCT04746209
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
Nkarta
NCT05020678
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Novartis Pharmaceuticals
NCT03876769
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL
University of Virginia
NCT03962465
A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults With B-Cell Acute Lymphoblastic Leukemia(B-ALL)
Memorial Sloan Kettering Cancer Center
NCT05460533
Venetoclax Plus Inotuzumab for B-ALL
Dana-Farber Cancer Institute
NCT05016947
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 2 | 6 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on B-cell Acute Lymphoblastic Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on B-cell Acute Lymphoblastic Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this B-cell Acute Lymphoblastic Leukemia page
22 registered trials, 17 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 17 B-cell Acute Lymphoblastic Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Colorado, Denver sponsors the most B-cell Acute Lymphoblastic Leukemia trials on record, review their full trial history before evaluating a specific study. See University of Colorado, Denver's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This B-cell Acute Lymphoblastic Leukemia condition card totals 22 registered trials; most-linked intervention Blinatumomab; top US site state Colorado. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.